Good First Line News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The use of the monoclonal antibody satralizumab for the long-term treatment of neuromyelitis optica spectrum disorder provides sustained freedom from relapse with no new safety concerns over 5 years.

United statesBritish columbiaUnited kingdomShailee shahAnthony traboulseeConsortium of multiple sclerosis centersNeuroimmunology division at vanderbilt university medical centerUniversity of british columbiaDrug administrationMultiple sclerosis centersMedscape medicalExpanded disability status scaleGood first lineMedscape medical newsNeuroimmunology divisionVanderbilt university medical center